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The persistence of the E7 oncoprotein in transformed cells in human papillomavirus (HPV)-associated cervical cancer provides a tumour-
specific antigen to which immunotherapeutic strategies may be directed. Self-replicating RNA (replicon) vaccine vectors derived from the
flavivirus Kunjin (KUN) have recently been reported to induce T-cell immunity. Here, we report that inclusion of a CTL epitope of HPV16
E7 protein into a polyepitope encoded by a KUN vector induced E7-directed T-cell responses and protected mice against challenge with an
E7-expressing epithelial tumour. We found replicon RNA packaged into virus-like particles to be more effective than naked replicon RNA or
plasmid DNA constructed to allow replicon RNA transcription in vivo. Protective immunity was induced although the E7 CTL epitope was
subdominant in the context of other CTL epitopes in the polyepitope. The results demonstrate the efficacy of the KUN replicon vector system
for inducing protective immunity directed towards a virally encoded human tumour-specific antigen, and for inducing multi-epitopic CTL
responses.
D 2004 Elsevier Inc. All rights reserved.Keywords: Kunjin virus; Replicon; Human papillomavirus; Virus-like particle vaccines; CTL; Polyepitope; E7 oncoprotein; TumourIntroduction
Human papillomaviruses (HPVs) are associated with a
variety of squamous cell cancers (zur Hausen, 2002). HPV
is detected in ca. 95% of cervical carcinomas, particularly
the ‘high-risk’ oncogenic genotypes HPV 16 and 18. The
protein products of the HPV genes E7 and E6 are principally
responsible for transforming cervical epithelial cells, by
binding to and abrogating the cell-cycle control functions
of cellular retinoblastoma protein and p53, respectively
(Scheffner et al., 1993; Slebos et al., 1994). This mode of
action requires that E7 and E6 proteins persist in order for
the cells to remain transformed (von Knebel et al., 1994),
and thus these viral proteins function as tumour-associated
antigens (TAAs), to which preclinical and clinical immuno-
therapeutic strategies are being directed. Cytotoxic T lym-
phocytes (CTLs) kill tumour cells displaying epitopes0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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in conjunction with major histocompatibility (MHC) mole-
cules. The CTL response to E7 protein induced by several
vaccine candidates, including peptides (Feltkamp et al.,
1995), plasmid DNA (Ji et al., 1999), viral vectors (Lin et
al., 1996), recombinant fusion proteins (Chu et al., 2000),
and chimeric virus-like particles (VLPs) (Chu et al., 2000;
Greenstone et al., 1998) is a determinant of HPV-associated
disease outcome in experimental murine tumours expressing
the HPV16 E7 gene (Feltkamp et al., 1995). Human MHC
restricted E7 CTL epitopes identified in human leucocyte
antigen (HLA) transgenic mice have successfully primed
CTLs from normal human donors (Da Silva et al., 2001),
and memory responses have been detected in some CIN and
cervical carcinoma patients but not in normal subjects
(Ressing et al., 1995). HLA restricted E7 peptides, and
recombinant vaccinia viruses expressing E6–E7 have been
tested in Phase 1 clinical trials in terminal cervical cancer
patients (Borysiewicz et al., 1996; Van Driel et al., 1999)
and E7 peptides have been tested in high–grade cervical
intra-epithelial neoplasia patients (Muderspach et al., 2000).
Generation of CTL, though generally disappointing in the
cervical cancer patients, was seen in some cases, and some
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1999). It is clear that more potent strategies for inducing
long-lived E7-directed CTLs, preferably against a broad
array of epitopes, are necessary for generating antitumour
responses.
We have previously constructed replication-incompetent
vaccine vectors or replicons derived from the Australian
flavivirus Kunjin (KUN) by removing the KUN structural
genes, and replacing them with a foreign gene (Khromykh
and Westaway, 1997; Khromykh et al., 1998; Varnavski and
Khromykh, 1999). The replicons retain replicase genes
which mediate RNA replication, and high-level foreign
protein expression, but produce no progeny virus. Repli-
con-based vectors display exclusively cytoplasmic replica-
tion (reviewed in Khromykh, 2000) eliminating putative
complications arising from nuclear splicing and chromo-
somal integration. Additionally, the inability of the replicon
RNA to escape from the transfected/infected cell precludes
vector spread in the vaccine recipient, rendering these
vectors biologically safe. The small genome size makes
replicon vectors easy to genetically manipulate, and mini-
mises vector-directed immune responses. There is generally
no preexisting immunity to KUN replicon vector determi-
nants in humans in most of the world, except the northern
parts of Australia where Kunjin virus is endemic. The
replicon system offers the further advantage that replicons
can be delivered either directly as naked RNA transcribed in
vitro, or as plasmid DNA encoding replicon cDNA under
the control of a mammalian expression promoter, or as RNA
packaged into virus-like particles (VLPs).
The KUN replicon packaging system utilises a replicon
expression vector derived from the unrelated Semliki Forest
virus (SFV) for production of KUN structural proteins, thus
eliminating potential problems associated with contamina-
tion of VLPs with infectious recombinant virus. A major
advantage of the KUN replicon system is that unlike the
highly cytopathic alphavirus replicon vectors commonly
used in immunisation studies (Bredenbeek et al., 1993;
Liljestrom and Garoff, 1991; Pushko et al., 1994, 1997),
KUN replicons are non-cytopathic, allowing prolonged
expression of inserted genes in vivo (Varnavski et al., 2000).
In the present study, we investigated the ability of the
KUN replicon system to deliver a polyepitope, known to be
immunogenic when delivered as DNA, which incorporated
a CTL epitope of the HPV16 E7 protein. We show that
although only moderate E7-directed T-cell responses were
induced, since the E7 epitope appeared to be subdominant to
other ‘stronger’ epitopes in the polyepitope, nonetheless, the
recombinant KUN replicons protected against the growth of
an E7-expressing epithelial tumour in immunised mice.
Immune responses and tumour protection were more pro-
nounced in mice immunised with replicon RNA packaged
into VLPs than naked replicon RNA or plasmid DNA
constructed to allow replicon RNA transcription in vivo.
Generically, the results demonstrate the efficacy of KUN
replicon vectors for inducing protective immunity directedto a virally encoded human tumour-specific antigen, and
suggest the possibility of simultaneous delivery of multiple
protective epitopes. Specifically, there are implications for
cervical cancer immunotherapy.Results
Construction and cellular expression of KUN replicons
encoding E7 CTL epitope
A polyepitope-encoding DNA vaccine, pSTMPDV, that
elicits multiple simultaneous CTL responses when used to
immunise mice has previously been reported (Thomson et
al., 1998). To create the immunogen used in the present
study, we elected to delete an epitope from pSTMPDV and
replace it with the H-2Db restricted CTL epitope RAHY-
NIVTF (denoted RAH/Db) (Feltkamp et al., 1995) of
HPV16 E7 oncoprotein. Two constructs were made, one
in which an ovalbumin CTL epitope (OVA) was deleted
from pSTMPDV and replaced with RAH/Db to create
E7+OVAMP and another in which a LCMV nucleoprotein
CTL epitope (LCMV) was deleted and replaced with RAH/
Db to create E7+LCMVMP (Fig. 1A). To compare the
efficacy of these constructs at eliciting E7-directed CTL
responses, restimulated splenocytes from H-2b mice immu-
nised with E7+OVAMP or E7+LCMVMP plasmid DNA
were reacted with target cells pulsed with RAH/Db peptide
in a 51Cr-release CTL assay. Immunisation with either
E7+OVAMP or E7+LCMVMP induced CTL responses
(Fig. 1A, i, ii). In this, and in a repeat experiment (not
shown), the former gave a somewhat better RAH/Db CTL
response however, and was therefore selected for incorpo-
ration in the KUN replicon system (Fig. 1B). We also
measured CTL responses to polyepitope peptides SGP/Db
and OVA/Kb (Fig. 1A).The responses were essentially
similar to those reported previously for these epitopes using
the unmodified polyepitope as immunogen (Thomson et al.,
1996), indicating that the E7 RAH/Db responses elicited
by E7+OVAMP and E7+LCMVMP were consistent with
other epitopes in the polyepitope.
KUN replicon RNA can be transcribed in vitro from
plasmid DNA containing the bacteriophage SP6 promoter
and delivered via transfection or injection as naked RNA
(Khromykh and Westaway, 1997). It can also be synthesised
in vivo by cellular RNA polymerase II from transfected or
injected plasmid DNA carrying a cytomegalovirus (CMV)
promoter (Varnavski et al., 2000) (Fig. 1B). In addition,
KUN replicon can be packaged into VLPs (Khromykh et al.,
1998) and delivered by infection. No matter how delivered,
once in the cytoplasm, KUN replicon initiates self-replica-
tion, leading to multiple RNA copies and increased expres-
sion of the inserted sequence (Anraku et al., 2002; Varnav-
ski et al., 2000).
Plasmid DNA containing KUN replicon cDNA encoding
E7+OVAMP, or KUN replicon RNA encoding E7+OVA
Fig. 1. (A) Schematic of mouse polyepitopes (single letter amino acid code), showing 10 CTL epitopes (boxed). MHC restriction of the CTL epitopes is
indicated as follows: H-2b (unshaded), H-2d (light grey), and H-2k (dark grey). In pE7+OVAMP, the SIINFEKL epitope (OVA/Kb) of pSTMPDV is replaced,
and in pE7+LCMVMP, the RPQASGVYM epitope of pSTMPDV is replaced with E7 epitope RAHYNIVTF (RAH/Db), respectively. Specific CTL response
following immunisation (im) of H-2b mice with pE7+OVAMP DNA (Ai) or pE7+LCMVMP DNA (Aii); percent cytotoxicity of cognate peptide-
restimulated splenocytes was measured by 51Cr-release assay using EL4.A2 target cells pulsed with RAH/Db (closed squares), OVA/Kb (closed triangles), SGP/
Db (closed circles), or unpulsed EL4.A2 (open symbols) at the indicated effector-to-target (E/T) cell ratios. (B) Schematic representation of KUN replicon
constructs. KUN replicon DNA and RNA vectors have the following features: 5Vand 3VUTRs (required for RNA replication); sequences encoding the first 20
amino acids of KUN C (C20) and the last 22 amino acids of KUN E (E22) structural proteins; sequences encoding all the nonstructural proteins (NS1, NS2A,
NS2B, NS3, NS4A, NS4B, and NS5) with Leu at amino acid position 250 of the NS1 gene product; a unique cloning site (MluI); either a CMV promoter (DNA
vector) or SP6 promoter (RNA vector) (to drive in vivo or in vitro expression, respectively); hepatitis delta virus anti-genomic ribozyme (HDVr) and the
polyadenylation signal from SV40 [poly(A)] inserted downstream of the 3VUTR (to ensure production of KUN replicon RNA molecules with precise 3Vtermini
for efficient initiation of replication); and the 2A autoprotease of foot-and-mouth disease virus (FMDV 2A) on both sides of the cloning site (to allow
cytoplasmic release of the cloned polytope from the -KUN C20 and E22 peptides). KUN replicon VLP vectors are composed of the capped RNA transcript
packaged by KUN core, envelope, and membrane structural proteins (not shown).
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transfected, electroporated, or infected, respectively, into
BHK21 cells. Expression of protein(s) encoded by the
KUN replicons was determined by immunofluorescence
using anti-KUN NS3 antibody. In all cases, NS3 proteinFig. 2. Immunofluorescence of BHK cells transfected with KUN replicon. BHK ce
0.4 Ag; (B) KUN replicon RNA encoding E7+OVAMP 0.4 Ag, or infected with
stained with antibody to KUN NS3 protein. Negative controls showing no specif
without first antibody (not shown).was detected in a proportion of cells (Figs. 2A–C). About
50% of cells were positive after transfection with DNA-
based replicon, 80% were positive after electroporation with
RNA-based replicon, and <1% were positive after infection
with KUN replicon VLPs at the multiplicity of infectionlls were transfected with (A) KUN replicon cDNA encoding E7+OVAMP,
(C) KUN replicon VLPs encoding E7+OVAMP at moi = 0.00025, and
ic staining were untransfected/uninfected cells or transfected/infected cells
K.A. Herd et al. / Virology 319 (2004) 237–248240(moi) of 0.00025 used. At moi of 10, ca. 100% of cells
infected with VLPs were positive (not shown), in agreement
with our previous findings (Anraku et al., 2002; Harvey et
al., 2003).
Relative induction of T-cell responses to encoded epitopes
following immunisation with KUN replicon cDNA encoding
E7+OVAMP
We wished to determine whether E7+OVAMP encoded
by KUN replicon cDNA would elicit a RAH/Db-specific
effector T-cell response, and to determine the magnitude of
this response relative to that of some of the other CTL
epitopes encoded by the polytope. We quantified, by ELI-
SPOT assay, epitope-specific interferon-gamma (IFN-g)-
secreting splenocytes ex vivo after one immunisation of H-
2b mice with KUN replicon DNA encoding E7+OVAMP.
IFN-g secretion is marker of antigen-specific effector T-cell
function. The RAH/Db response was markedly lower than
the SGP/Db response (Figs. 3A–C), suggesting immunodo-
minance of the latter epitope. The response to RAH/Db was
also lower than that to ASN/Db (Fig. 3C). Additionally,
immunisation of H-2d mice with KUN replicon DNA encod-
ing E7+OVAMP produced a strong response to one of the
two H-2d-restricted epitopes tested (SYI/Kd, Figs. 3D, E),
and this response was considerably larger than the RAH/Db-
directed response (Fig. 3A) in H-2b mice. Together, these
data suggest that RAH/Db is subdominant to at least one
other H-2b restricted epitope, and is not a ‘strong’ epitope
relative to another epitope (SYI/Kd) in the context of
E7+OVA mouse polyepitope.
Induction of T-cell responses to RAH/Db following
immunisation with KUN replicon DNA, KUN replicon RNA,
and KUN replicon VLPs
We asked whether better T-cell responses to RAH/Db
than those evoked by KUN replicon DNA could be evoked
by KUN replicon RNA or KUN replicon VLPs, and whether
a second immunisation would improve responses. WeFig. 3. Epitope-specific IFN-g-secreting T-cell response following immunisation w
once (im) with KUN replicon cDNA encoding E7+OVAMP. IFN-g- secreting cel
immunisation, and incubated for 15–18 h with (closed bars) or without (open baimmunised H-2b mice with KUN replicon DNA encoding
E7+OVAMP, with KUN replicon RNA encoding
E7+OVAMP, or with KUN replicon VLPs encoding
E7+OVAMP (two doses), and measured RAH/Db- and
SGP/Db-specific splenocytes ex vivo, after one or two
immunisations. The responses were greater after two immu-
nisations (Figs. 4A, B). Epitope-specific responses were
recorded with an order of efficacy of KUN replicon
VLPs > KUN replicon RNA > KUN replicon DNA. In
agreement with the above findings, the RAH/Db response
was subdominant to the SGP/Db response. However, the
RAH/Db-specific response evoked by KUN replicon VLPs
encoding E7+OVAMP was similar in magnitude to that
evoked by immunisation with RAH/Db peptide, and was
superior to that evoked by immunisation with conventional
E7+OVAMP DNA (Fig. 4B). Immunisation with the higher
dose of VLPs (2  106) gave stronger responses to both
epitopes than immunisation with the lower dose (5  105)
(Fig. 4B). These data demonstrate the superiority of KUN
replicon VLPs encoding E7+OVAMP over KUN replicon
RNA and KUN replicon DNA in delivering the RAH/Db
epitope for an epitope-specific IFN-g-secreting T-cell re-
sponse. They also suggest the induction of a memory T-cell
response following first immunisation which is recalled by
subsequent immunisation.
We wished to determine whether immunisation with the
recombinant KUN replicons would induce specific T-cell
responses to the subdominant RAH/Db epitope, measurable
in a functional cytotoxicity assay. Mice were immunised
with KUN replicon DNA encoding E7+OVAMP, with
KUN replicon RNA encoding E7+OVAMP, or with
KUN replicon VLPs encoding E7+OVAMP. Splenocytes
from immunised mice were restimulated in vitro with
RAH/Db peptide or SGP/Db peptide, and reacted with
RAH/Db-pulsed, with SGP/Db-pulsed, or unpulsed target
cells in 51Cr-release CTL assay. Strong epitope-directed
CTL responses were recorded after two immunisations. The
response to the immunodominant SGP/Db epitope (Fig. 5D)
exceeded the marginal response of the subdominant RAH/
Db epitope (Fig. 5C). In agreement with the ELISPOTith KUN replicon. H-2b mice (A–C) or H-2d mice (D, E) were immunised
ls were quantified by ELISPOT assay of splenocytes harvested 14 days after
rs) specific peptide.
Fig. 4. Epitope-specific IFN-g-secreting T-cell response following immunisation with KUN replicon. H-2b mice were immunised once (A) or twice (B) with
conventional plasmid pE7+OVAMP (conv DNA) (im), with KUN replicon cDNA encoding E7+OVAMP (rep DNA) (im), with KUN replicon RNA
encoding E7+OVAMP (rep RNA) (im), or with KUN replicon VLPs encoding E7+OVAMP (rep VLPs at 5  105 or 2  106 per mouse, ip), as indicated.
Control mice were immunised subcutaneously with multi-peptide (see Materials and methods) or unimmunised. IFN-g cells were quantified by ELISPOT assay
using splenocytes harvested at 14 days (DNA, RNA, and VLP immunisations) or at 10 days (multi-peptide immunisation) after immunisation, and incubated
for 15–18 h with or without specific peptide (RAH/Db or SGP/Db) as shown. Numbers represent the Activation Index (< denotes less than 2 and is not
significant); nt represents not tested.
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a stronger SGP/Db-directed cytotoxic response than that
induced by 5  105 VLPs (Fig. 5D). These data indicateFig. 5. Epitope-specific CTL response following immunisation with KUN replicon
cDNA encoding E7+OVAMP (rep DNA) (im), with KUN replicon RNA encod
E7+OVAMP (rep VLP at 5  105 or 2  106 per mouse, ip), as indicated. Per
restimulated with RAH/Db-pulsed (A, C) or SGP/Db-pulsed (B, D) lymphoblasts
RAH/Db or SGP/Db or no peptide (none) as shown. Numbers above the data
cytotoxicity of peptide-coated target cells minus percentage of cytotoxicity of unthat two immunisations with polyepitope-encoding KUN
replicon DNA, replicon RNA, or replicon VLPs elicit
functional CTL responses.. H-2b mice were immunised once (A, B) or twice (C, D) with KUN replicon
ing E7+OVAMP (rep RNA) (im), or with KUN replicon VLPs encoding
cent cytotoxicity of splenocytes harvested 3 weeks after immunisation and
was measured in 51Cr-release assay using EL4.A2 target cells pulsed with
points indicate the percentage of specific cytotoxicity (i.e., percentage of
coated target cells).
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E7+OVAMP retards the growth of E7-expressing tumour
To determine whether immunisation with KUN replicon
expressing the E7 epitope would protect against tumour,
mice were immunised twice with KUN replicon RNA
encoding E7+OVAMP, or with KUN replicon VLPs encod-
ing E7+OVAMP, and challenged with 2  105 E7-express-
ing TC-1 tumour cells 2 weeks after the second
immunisation. Control mice were immunised with RAH/
Db peptide or unimmunised. All mice in the unimmunised
control group had acquired palpable tumour by day 7. In
contrast, four out of five mice immunised with KUN
replicon VLPs encoding E7+OVAMP remained tumour-
free at day 70 (P = 0.0143) (Fig. 6). The rate of tumour
development was one fifth of that for unimmunised mice
(hazard ratio = 0.2). This level of tumour protection was not
significantly different (P = 0.317) from that observed in
mice immunised with a vast molar excess (30 Ag) of peptide
encoding the minimal CTL epitope RAH/Db (Fig. 6). In
mice immunised with KUN replicon RNA encoding
E7+OVAMP, tumour growth was also retarded compared
to unimmunised mice. Three of five mice remained tumour-
free at 7 days, and one out of five mice remained tumour-
free at 70 days (P = 0.049) and the tumour development rate
was ca. one half of that observed for unimmunised mice
(hazard ratio = 0.59). To determine whether E7-directed
tumour immunity persisted, immunised mice which were
free of tumour at 70 days were re-challenged with tumour.
None of the mice from groups immunised with KUN
replicon VLPs encoding E7+OVAMP or with KUN repli-
con RNA encoding E7+OVAMP developed tumour (data
not shown). In contrast, five out of five unimmunised
identically challenged control mice developed tumour. To-
K.A. Herd et al. / Viro242Fig. 6. Growth of E7-expressing tumour (TC-1) in H-2b mice immunised
twice on the days indicated with KUN replicon RNA encoding
E7+OVAMP (rep RNA) (im), or with KUN replicon VLPs encoding
E7+OVAMP (rep VLP at 2  106 per mouse, ip). Control mice were
immunised with 30 Ag RAH/Db peptide + tetanus toxoid + Quil A adjuvant
(sc) or unimmunised. Mice were challenged (sc) with 2  105 TC-1 cells on
day 0. Results are expressed as tumour-free mice (%) at the indicated time
points.gether, these data indicate that immunisation with KUN
replicon expressing the E7 epitope protects against growth
of an E7 tumour challenge, and suggests that the tumour
protective immunity is long lived.Discussion
In this study, we have constructed KUN virus replicons
to deliver a CTL epitope of a viral oncoprotein (HPV16 E7)
in the context of an immunogenic polyepitope. We have
engineered the replicons to be administered either as naked
RNA, plasmid DNA constructed to allow replicon RNA
transcription in vivo, or RNA packaged into infectious but
propagation-incompetent VLPs. Introduction of each of
these into cells in vitro resulted in similar high levels of
cytoplasmic expression (Fig. 2 and Anraku et al., 2002). We
demonstrate the generation of specific T-cell responses and
protection against growth of an E7-expressing epithelial
tumour in replicon-immunised mice. We found VLPs to
be more effective than naked RNA or plasmid DNA.
Protective immunity was induced although the E7 CTL
epitope was subdominant in the context of other CTL
epitopes in the polyepitope. The response was boosted by
a second immunisation.
An important feature of the KUN replicon system is that
modified KUN genetic material is self-replicating in cells
(Anraku et al., 2002), and, unlike other alphavirus replicons,
KUN replicons are non-cytopathic (Khromykh and West-
away, 1997), thus facilitating continuous and ongoing
presentation of encoded immunogen to the recipient’s im-
mune system, with possible consequences for long-term
generation of effector T-cell responses and maintenance of
T-cell memory. We have previously shown that h-galacto-
sidase expression from an intranasally administered KUN-
h-galactosidase DNA-based vaccine persisted undiminished
in mouse lung epithelium for at least 2 months (Varnavski et
al., 2000). It may however be argued that cytopathicity as
seen during infection with alphavirus replicons may foment
a cytokine-mediated inflammatory milieu conducive to
adaptive immune response induction.
The KUN replicon system offers further putative advan-
tages. Unlike alphaviruses (Hill et al., 1997), flaviviruses in
general show no evidence of recombination between differ-
ent viruses or virus strains, a feature of potential importance
in vaccine recipients who may be infected with the same or
other flaviviruses around the time of immunisation. Further-
more, the system for KUN VLP generation uses unrelated
SFV for production of KUN structural proteins, which
together with the specific design of the expression construct
(Khromykh et al., 1998; Varnavski and Khromykh, 1999)
precludes possible contamination of VLPs with infectious
recombinant material. Additionally, the lack of ongoing
production of KUN structural proteins and small genome
size minimises the opportunity for development of vector-
directed immunity, a possible drawback of other replicating
K.A. Herd et al. / Virology 319 (2004) 237–248 243viral vectors (e.g., vaccinia), which might preclude second
or subsequent immunisation.
The above features not only ensure the effective and
long-term delivery of epitopes, but would also predispose to
the safety of the KUN replicon system for delivery of whole
oncoproteins, for example, full-length E7. A further advan-
tage is the relatively small size of the KUN replicon (in
comparison to other viral vectors) which makes it easy to
manipulate.
We elected to replace a OVA or a LCMV epitope in the
original polyepitope with the E7 epitope because robust
CTL killing directed to the former two epitopes was
demonstrable in mice immunised with the parent polyepi-
tope DNA (Thomson et al., J. Immunol. 1996). The
responses obtained to the E7 epitope in mice immunised
with the engineered polytope were of lesser magnitude
when compared with OVA or LCMV epitopes and with
some other epitopes in the polyepitope (Figs. 3 and 4). The
‘weak’ response to the E7 epitope was maintained irrespec-
tive of whether the polyepitope was delivered as conven-
tional DNA, KUN replicon DNA, KUN replicon RNA, or
KUN replicon VLPs (Fig. 4). While positioning of an
epitope within a DNA polyepitope may affect the magnitude
of the CTL response to that epitope (Ishioka et al., 1999),
the rules governing this phenomenon are not worked out. It
is well established that a hierarchy of CD8 T-cell responses
from subdominant to dominant can be seen following
polyepitope vaccination (Anraku et al., 2002; Le et al.,
2001), though whether dominant responses effectively sup-
press or interfere with induction of less dominant responses
remains controversial. While deletion of more dominant
epitopes in our polyepitope may improve the response to
the E7 epitope, there is data to show that removal of a
dominant epitope did not improve responses to a subdom-
inant epitope within the same polyepitope vaccine (Suhrbier,
2002). Alternatively, the lower response we report to the E7
epitope may simply reflect that the E7 epitope is constitu-
tively not a ‘strong’ epitope (Doan et al., 1998; Feltkamp et
al., 1995) rather than its position within the engineered
polyepitope.
In spite of the weak response to the E7 epitope RAH/Db,
immunisation with KUN replicon VLPs encoding
E7+OVAMP completely protected 80% of mice against a
dose of E7-expressing tumour cells which gave 100% tumour
incidence in unimmunised mice (Fig. 6). Additionally, immu-
nisation with E7+OVAMP KUN replicon as naked RNA
delayed tumour growth in some mice, and completely pro-
tected one (of five) mice (Fig. 6). All completely protected
mice remained tumour-free 70 days after challenge. Further-
more, they retained tumour immunity because all rejected a
second TC-1 tumour challenge at this time. These data
emphasise the efficacy of induction of tumour protection
by the KUN replicon system encoding a tumour antigen, and
further suggest the induction of a long-term memory re-
sponse. Other studies in our laboratory indicate that specific
memory responses in mice immunised once with KUNreplicon encoding a murine polyepitope or HIV-1 gag may
be recalled undiminished until at least 6 months by in
vitro restimulation of splenocytes (Harvey et al., 2003).
We surmise that the long-lived expression due to the non-
cytopathic infection unique to the KUN replicon system
contributes to the observed long-lived memory.
We have not excluded the possibility that although the
measured T-cell response directed to RAH/Db is weak
compared to SGP/Db, the former T cells could have high
avidity, which perhaps might explain their efficacy in
tumour protection. Furthermore a differential expansion of
RAH/Db- and SGP/Db-specific T cells without effector
function might contribute to the discrepancy between T-cell
responses measured in vitro and in vivo. Overall, our
findings are congruent with other studies indicating that
effective protection against certain diseases may be ade-
quately mediated by subdominant memory responses that
are amplified after challenge (Le et al., 2001; Moss et al.,
1996).
We have experiments planned to investigate whether
immunisation with recombinant KUN replicons express-
ing the E7 CTL epitope will have a therapeutic effect on
E7-associated carcinomas which develop in mice express-
ing an E7 transgene specifically in the basal and supra-
basal cells of squamous epithelium (Herbert et al., 1996).
These mice constitute a model for HPV-associated human
squamous carcinoma of the uterine cervix (Frazer et al.,
1995).
The above results, and our previous data (Anraku et al.,
2002), demonstrating concomitant CTL responses to many
epitopes encoded by KUN replicon, suggest the possibility
of broad-based therapy afforded by a polyepitope con-
structed to express multiple HPV epitopes targeting other
oncogenic HPV genotypes and HLA restriction elements.
Such a vaccine would be applicable to a diversely HPV-
infected and out-bred human population. Because replicon-
initiated tumour protection is mediated by CTLs directed to
tumour epitopes (Cheng et al., 2002), our observation that
ostensibly weak responses translate into strong tumour
protection may be of particular relevance for humans in
which E7 HLA-restricted epitopes do not elicit powerful
CTL responses either in E7-expressing cervical carcinoma
patients (Ressing et al., 1995) or in recipients of E7 peptide
vaccines (Van Driel et al., 1999).
In agreement with our previous findings (Anraku et al.,
2002), the in vitro T-cell responses induced by KUN
replicon VLP and KUN replicon RNAwere superior to that
induced by conventional DNA immunisation (Fig. 4B).
[Note that in preliminary experiments, we determined the
optimal delivery route for each. In the present study, we
compared vaccine efficacy using the optimal route for RNA
(im), DNA (im), VLPs (ip), and peptide (sc).] While we
have previously reported (Anraku et al., 2002) that compa-
rable levels of T-cell induction to another encoded immu-
nogen required a 1000-fold higher dose of conventional
plasmid DNA vaccine compared to KUN replicon DNA, the
K.A. Herd et al. / Virology 319 (2004) 237–248244difference was not so large in the present study. The
response induced by KUN replicons may depend on the
nature of the encoded immunogen, as it does for DNA based
alphavirus replicons (Berglund et al., 1997; Hariharan et al.,
1998). It is noteworthy that KUN replicon encoding
E7+OVAMP elicited somewhat better T-cell responses
(Figs. 4B, 5) when administered as naked RNA than as
plasmid cDNA.
We have previously reported that 5- to 10-fold higher
amounts of KUN-specific RNAs were produced in cells
transfected with a plasmid DNA encoding replication-com-
petent KUN replicon RNA compared with a plasmid DNA
encoding a replication-deficient KUN replicon RNA (Var-
navski et al., 2000). Increased levels of KUN RNA corre-
lated with increase KUN protein production in cells
measured by immunofluorescence (Khromykh and West-
away, 1997; Khromykh et al., 1998). These findings likely
contribute to the enhanced responses elicited to replicon-
encoded antigen versus antigen encoded in a conventional
nonreplicating nucleic acid vaccine reported in our present
and previous (Anraku et al., 2002) studies. KUN replicon
VLPs encoding E7+OVAMP elicited stronger T-cell
responses to polyepitope [measured either as ex vivo IFN-
g ELISPOTS (Fig. 4) or as 51Cr-release CTL after restim-
ulation in vitro (Fig. 5)], and better tumour protection, than
KUN replicon RNA (Fig. 6). This suggests that VLPs may
be the preferred mode of replicon delivery. The observed
superiority of KUN replicon VLPs likely also relates to
enhanced delivery of replicon RNA to APCs using this
vaccine modality compared with KUN replicon adminis-
tered as plasmid DNA or naked RNA. The encapsidation of
replicon RNA into VLPs by the corresponding viral struc-
tural proteins prevents RNA degradation and may provide a
more efficient delivery of replicon RNAvia infection, which
mimics the normal virus entry pathway. Immunofluorese-
cence analysis of BHK21 cells with KUN anti-NS3 anti-
body showed the highest percentage of positive cells after
infection with KUN replicon VLPs (ca. 100% at moi = 10)
and the least after transfection with plasmid DNA-based
replicon (ca.50%).
Significant tumour protection afforded by naked RNA
immunisation has been reported in various tumour models
(Anraku et al., 2002; Ying et al., 1999). Although naked
RNA offers advantages over DNA in avoiding potential
DNA integration, and over VLPs in avoiding putative VLP-
directed antibody and CTL induction, naked RNA vaccines
have the disadvantages of instability and difficulties of
preparation.
Effective booster immunisation using a second inocula-
tion with the same virus vector-based vaccine usually
demands that the primary immunisations did not lead to
the production of neutralising antibodies. In another study,
we have specifically investigated whether there was any
significant neutralising antibody response to KUN enve-
lope VLP protein after two immunisations with KUN
VLPs encoding a foreign protein (HIV gag). We showedthat although VLP infectivity was completely neutralised
by anti-VLP monoclonal antibody, sera from mice immu-
nised twice with KUNgag VLPs showed no significant
neutralising activity above that recorded for sera from
unimmunised (control) mice (Harvey et al., 2003). Addi-
tionally, preexisting CD8+ T-cells specific for vaccine
vector or encoded vaccine antigen do not usually influence
the efficacy of CTL induction to encoded antigen follow-
ing subsequent immunisation (Sherritt et al., 2000). These
observations indicate that repeated immunisations with
KUN VLPs to boost protective responses to encoded
antigen are feasible.
The polyepitope response following replicon VLP
immunisation was dose dependent (Fig. 4B), with 2 
106 VLPs being more effective than 5  105 (Figs. 4B and
5). Our most recent data show that even higher CTL
responses can be induced by increasing the VLP dose
further (not shown).
Daemen et al. (2002) investigated the immunotherapeu-
tic potential of recombinant SFV alphavirus replicons
expressing full-length HPV16 E6 and E7, and reported
somewhat less robust tumour protection than we found in
our studies (40% of their mice were tumour-free after three
immunisations with a 10-fold higher VLP dose, using a
10-fold less TC-1 tumour cell challenge, than used in our
experiments). While differences in experimental conditions
(e.g., number of moles of immunogenic epitope available,
the cellular tropism of alphavirus VLPs versus KUN
VLPs, etc.) will have determined outcome, nonetheless,
the results underscore the comparative high efficacy of the
KUN replicon VLPs at inducing tumour protection. Sim-
ilar or greater levels of E7-directed tumour protection
have been recorded following immunisation with Vene-
zuelan Equine Encephalitis replicon VLPs (Velders et al.,
2001) and Sindbis virus replicon VLPs encoding full-
length E7 protein. The latter required E7 protein fused
to a Herpes simplex tegument protein which facilitated the
spread of E7 antigen to neighbouring cells following
apoptosis of cells ‘infected’ by immunisation (Cheng et al.,
2002).
We did not investigate the requirement for CD4+ T-
‘help’ or CD40 dependency in induction of CTL responses
by E7 epitope recombinant KUN replicon. There are data to
suggest that CTL induction by the polyepitope protein is T-
help independent (Thomson et al., 1998). Furthermore,
RAH/Db-directed CD8+ CTL induction by peptide (Doan
et al., 1998) or whole E7 protein (Fernando et al., 1998)
does not require concomitant CD4+ T-cell activation. How-
ever, in those cases where CD4+ T help might be required,
for example, for HLA A*0201-restricted E7 CTL epitopes
(Ressing et al., 2000), or in the rejection of established
tumours (Fernando et al., 1998), ‘help’ may be provided
from T-helper epitopes within the KUN nonstructural pro-
teins, or by incorporating a universal T-helper epitope
encoding sequence in the inserted gene (Ressing et al.,
2000).
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CTL epitope into a polyepitope encoded by a KUN replicon
vector used for immunisation induced E7-directed T-cell
responses as measured by g-IFN secretion and cytotoxicity,
and afforded mice with protection against challenge with an
E7-expressing epithelial tumour. We found that replicon
RNA packaged into VLPs was more effective than naked
replicon RNA or plasmid cDNA constructed to allow repli-
con RNA transcription in vivo. Generically, the results
demonstrate the efficacy of KUN replicon vectors for induc-
ing immunity against multiple inserted epitopes, and protec-
tive immunity against a clinically relevant viral antigen
subdominant in the context of co-inserted epitopes. Specif-
ically, there are implications for the generation of effective
therapeutic immunity for HPV-associated neoplastic disease.Materials and methods
Plasmids
Conventional DNA plasmids, pE7+OVAMP and
pE7+LCMVMP, were created by site-directed mutagenesis
of pSTMPDV (Thomson et al., 1998) which encodes a
mouse polytope, comprising 10 minimal CTL epitopes and
one B cell epitope (Fig. 1A). Substitution primers were
designed to introduce the H-2Db restricted CTL epitope
of HPV16E7 (49RAHYNIVTF57) (Feltkamp et al., 1995)
at either the OVA or LCMV site. A recombination PCR
approach (Jones and Howard, 1991) was used, so primer
pairs had 5V ends with overlapping sequences encoding
the mutation (underlined) and 3V ends complementary to
the template adjacent to the deletion site (shown in bold).
For the OVA mutation, primers (5V!3V) were: AGG GCC-
CAC TAC AAC ATC GTG ACC TTC ACC TAC CAG
AGG ACC AGG (forward); GAA GGT CAC GAT GTT-
GTA GTG GGC CCT CAT AGC GTC CAT GTT CTC
(reverse). For the LCMV mutation, primers (5V!3V) were:
AGG GCC CAC TAC AAC ATC GTG ACC TTC CCT
AGG AAC AAC CTG GT (forward); GAA GGT CAC-
GAT GTT GTA GTG GGC CCT GAT CTC ACC GAC
GAT GGC (reverse). Linear PCR product with double-
stranded homologous ends was purified with a QIAquick
gel extraction kit (QIAGEN, Clifton Hill, VIC, Australia)
and used to transform competent E. coli (MaxEfficiency
DH5a, Invitrogen, Melbourne, VIC, Australia). Plasmid
DNA was sequenced to confirm the mutation before the
polytope was subcloned into KUN replicon vectors. The
polytope sequence was amplified from pE7+OVAMP tem-
plate by high-fidelity PCR with Pfu DNA polymerase and
subcloning primers designed to introduce MluI sites (shown
in bold) at both ends. Primers (5V!3V) were: GCG ACG
CGT CTA GAG CCA GCA ACG AGA A (Mpt-F); GTA
ACG CGT CTA AGT CCT CGG GGC CGG (Mpt-R). The
PCR product was digested with MluI and cloned into
replicon DNA and RNA vectors (Fig. 1B). Restrictionenzyme analysis as well as DNA sequencing confirmed
the presence and orientation of the polyepitope.
Cell lines and peptides
Cells were cultured in DMEM (Invitrogen) with 20 mM
HEPES, 2 mM L-glutamine (GlutaMax I, Invitrogen), 1 mM
sodium pyruvate, 100 IU/ml penicillin, 100 Ag/ml strepto-
mycin, 50 AM 2-mercaptoethanol, and 10% foetal bovine
serum. Baby hamster kidney cells (BHK21) were used for
replicon expression studies and Vero cells for titration of
VLPs. The EL4.A2 target cell line (H-2b thymoma) (Doan et
al., 1998) and the TC-1 cell line (primary lung epithelial
cells from C57BL/6 mice transformed with HPV16 E6 and
E7 and activated ras oncogene) (Lin et al., 1996) have been
described previously.
Peptides (synthesised by Mimotopes, Clayton, VIC,
Australia) were: the H-2Db restricted epitopes from
HPV16E7 49RAHYNIVTF57 (denoted RAH/Db), Adenovi-
rus 5 E1A 234SGPSNTPPEI243 (denoted SGP/Db), and
influenza nucleoprotein 366ASNENMDAM374 (denoted
ASN/Db); the H-2Kb restricted epitope from ovalbumin
257SIINFEKL264 (denoted OVA/Kb); the H-2Kd restricted
epitope from Plasmodium berghei circumsporozoite protein
249SYIPSAEKI257 (denoted SYI/Kd); and the H-2Ld restrict-
ed epitope from lymphocytic choriomeningitis virus
(LMCV) nucleoprotein 118RPQASGVYM126 (denoted
RPQ/Ld).
DNA and RNA transfection, immunofluorescence analysis
For DNA transfections, BHK21 cell monolayers were
transfected with 0.4 Ag plasmid DNA, using Lipofectamine
Plus (Invitrogen), as described by the manufacturer. For
RNA transfections, RNA was transcribed in vitro from
XhoI-linearised template DNA using SP6 RNA polymerase
(Roche, Castle Hill, NSW, Australia) and capping ana-
logue, m7G(5V)ppp(5V)G (New England BioLabs, Beverly,
MA) and then electroporated into BHK21 cells as de-
scribed previously (Khromykh and Westaway, 1997). After
48 h, cells were fixed in cold acetone and analysed for
expression of KUN NS3 protein by indirect immunofluo-
rescence (IF) as described previously (Westaway et al.,
1997).
Preparation of DNA and RNA vaccines
DNA vaccines were prepared using an EndoFree plasmid
mega kit (QIAGEN) and quality assured by agarose gel
electrophoresis. RNA vaccines were prepared using a com-
mercially available kit (mMessage mMachine SP6 transcrip-
tion kit, Ambion, Austin, TX) and the recommended
protocol for long transcripts at a CAP/GTP ratio of 2:1.
Transcribed RNA was used after DNase treatment, but
without further purification and was quality assured by
denaturing agarose gel electrophoresis.
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KUN replicon VLPs were produced as described previ-
ously (Khromykh and Westaway, 1997; Khromykh et al.,
1998; Varnavski and Khromykh, 1999) by sequential trans-
fection of BHK21 cells with in vitro transcribed RNA.
Briefly, BHK21 cells were electroporated in the presence
of KUN replicon RNA using a Gene Pulser II and Pulse
Controller (Bio-Rad, Regents Park, NSW, Australia), then
cultured for 32 h. Cells were then trypsinised and electro-
porated again under the same conditions, with SFV replicon
RNA expressing the KUN structural proteins (SFV
MEC105) (Khromykh et al., 1998). After a further 40 h in
culture, medium was collected, clarified by low-speed
centrifugation, and VLPs were snap-frozen in dry-ice/etha-
nol, either immediately or after purification on a discontin-
uous sucrose density gradient. VLP titre was determined by
infecting Vero cell monolayers with a series of decimal
dilutions and performing immunofluorescence and analysis
after 30 to 40 h. Typically, the titre of unpurified VLPs was
7  106 IU/ml.
Immunisation of mice
H-2b (A2.1Kb) and H-2d (BALB/c) female mice (6 to
8 weeks) were supplied by Animal Resources Centre
(Perth, WA, Australia) and maintained under specific path-
ogen-free conditions. All experiments were conducted with
approval from the University of Queensland (Australia),
Animal Ethics Committee. DNA vaccines (100 Ag resus-
pended in 100 Al of 0.9% NaCl) or RNA vaccines (50 Ag
diluted to 100 Al with nuclease-free 0.9% NaCl, 10 mM
HEPES) were injected intramuscularly, using 50 Al in each
quadriceps muscle, under anaesthesia with ketamine/xyla-
zine. The doses were chosen from preliminary experiments
to give maximal CTL responses for these vaccines. VLP
vaccines (5  105 or 2  106 IU in <0.5 ml) were injected
intraperitoneally. Mice were immunised at 28 and 14 days
before immune status evaluation. Multi-peptide vaccines
(30 Ag each peptide, 0.25 Ag tetanus toxoid, 10 Ag Quil A,
diluted in PBS to 100 Al) were injected once subcutane-
ously at the tail base 10 days before immune status
evaluation.
T-cell assays for IFN-c release and cytotoxicity
Epitope-specific gamma interferon (IFN-g)-secreting
spleen cells were enumerated ex vivo by an enzyme-linked
immunospot (ELISPOT) assay with minimal CD8+ T-cell
epitope peptides, essentially as described previously (Le et
al., 2001). Microwell plates (MultiScreen-HA, Millipore,
North Ryde, NSW, Australia) were coated with capture
antibody (rat anti-mouse IFN-g, clone RA-6A2, BD Phar-
Mingen, San Diego, CA), blocked with DMEM 10% FBS,
and washed. Serial dilutions of spleen cells, starting at 106/
well were added, with 100 U/ml recombinant human inter-
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with 10 Ag/ml peptide or without, for 15–18 h at 37 jC. The
cells were then lysed, the plates washed, and detection
antibody (biotinylated anti-mouse IFN-g, clone XMG 1.2,
BD PharMingen) was added for 2 h. at 37 jC. After further
washing, plates were developed using streptavidin-alkaline
phosphatase (BD PharMingen) and BCIP-NBT substrate
(Sigma FAST 5-bromo-4-chloro-3-indolylphosphate-nitro-
blue tetrazolium). IFN-g spots were counted using an AID
EliSpot reader system. Results were calculated as IFN-g-
positive cells/106 spleen cells. Activation index was defined
as the mean (n = 3) frequency of spots with peptide, divided
by the frequency of spots without peptide and was consid-
ered significant if greater than two.
Epitope specific cytotoxicity of spleen cells was deter-
mined by 51Chromium (51Cr)-release CTL assay as de-
scribed (Doan et al., 1998). Ex vivo spleen cells from
immunised mice were depleted of professional APCs by
plastic adherence and restimulated by co-culture with pep-
tide-loaded lymphoblasts at a ratio of 10:1. Lymphoblasts
were spleen cells that had been activated for 3 days with 25
Ag/ml lipopolysaccharide (Sigma) and 7 Ag/ml dextran
sulphate, then irradiated (3000 rad) and incubated with 10
Ag/ml individual peptide for 90 min. After 6 days restimu-
lation, effector cells were reacted at the specified effector-
to-target cell (E:T) ratios with 51Cr-labelled EL4.A2 target
cells which had been loaded with 10 Ag/ml peptide, or
without. After 4–6 h incubation, radioactivity (cpm) in 100
Al of cell-free supernatant was determined by gamma
counting. Percentage of cytotoxicity F standard deviation
was calculated using the formula (E  S) / (T  S)  100,
where E represents cpm released in the presence of effector
cells, S represents spontaneous cpm with medium only, and
T represents total cpm in the presence of 5% sodium
dodecyl sulphate. S values were always less than 15% of
T. Peptide specific cytotoxicity was defined as the difference
between the mean (n = 3) cytotoxicity against targets with
peptide and without.
Tumour protection assay
Groups of H-2b mice (n = 5) were immunised twice
before TC-1 cells (2  105 in 0.1 ml Hank’s buffered salt
solution) were injected subcutaneously on the left flank
using a 21 gauge needle. (The tumour dose was predeter-
mined by titration experiments to discern a minimal dose
giving rise to tumour in 100% of unimmunised mice.)
Tumour growth was monitored every 3 days, and mice
were euthanised when tumour volume exceeded 1000
mm3. The time when mice developed palpable tumour
was noted and represented in Kaplan–Meier survival
curves (Lemeshow, 1999). Differences between the curves
were calculated using the log rank statistic and a hazard
ratio at a 95% confidence interval. At 70 days post-
challenge, the tumour-free mice were re-challenged with
TC-1 cells injected subcutaneously on the right flank.
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